Peter Paul van Geel
University Medical Center Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Paul van Geel.
Circulation | 2004
Saraswati Pokharel; Peter Paul van Geel; Umesh Sharma; Jack P.M. Cleutjens; Holger Bohnemeier; Xiao-Li Tian; Heribert Schunkert; Harry J.G.M. Crijns; Martin Paul; Yigal M. Pinto
Background—Although increased activity of angiotensin-converting enzyme (ACE) has been associated with increased cardiac collagen, no studies to date have established a direct cause-and-effect relation between the two. Methods and Results—We used transgenic rats that overexpress human ACE selectively in the myocardium. Two independent heterozygous transgenic rat lines were studied, one expressing 2 to 3 copies (L1172) and the other expressing 5 to 10 copies (L1173) of the ACE transgene. These rats were normotensive but developed a proportionate increase in myocardial collagen depending on the ACE gene dose (up to 2.5-fold, P<0.01), but cardiac angiotensin II levels remained normal, whereas collagen content reversed to control levels on ACE inhibition. To explain these changes, we investigated N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), an alternative substrate that is catabolized exclusively by ACE. Increased cardiac expression of ACE was paralleled by a reciprocal decrease in cardiac AcSDKP and a proportionate increase in phosphorylated Smad2 and Smad3, all of which normalized after both ACE inhibition and AcSDKP infusion. Furthermore, a functional link of this signaling cascade was demonstrated, because AcSDKP inhibited Smad3 phosphorylation in a dose-dependent manner in cultured cardiac fibroblasts and in vivo. Conclusions—Our findings suggest that increased cardiac ACE activity can increase cardiac collagen content by degradation of AcSDKP, an inhibitor of the phosphorylation of transforming growth factor-&bgr; signaling molecules Smad2 and Smad3. This implies that the antifibrotic effects of ACE inhibitors are mediated in part by increasing cardiac AcSDKP, with subsequent inhibition of Smad 2/3 phosphorylation.
Journal of Molecular Medicine | 2001
Sigrid Hoffmann; Thomas Krause; Peter Paul van Geel; Roland Willenbrock; Ines Pagel; Yigal M. Pinto; Hendrik Buikema; Wiek H. van Gilst; Carsten Lindschau; Martin Paul; Tadashi Inagami; Detlev Ganten; Hidenori Urata
Abstract. Angiotensin II is known to stimulate cardiac hypertrophy and contractility. Most angiotensin II effects are mediated via membrane bound AT1 receptors. However, the role of myocardial AT1 receptors in cardiac hypertrophy and contractility is still rarely defined. To address the hypothesis that increased myocardial AT1 receptor density causes cardiac hypertrophy apart from high blood pressure we developed a transgenic rat model which expresses the human AT1 receptor under the control of the α-myosin heavy-chain promoter specifically in the myocardium. Expression was identified and quantified by northern blot analysis and radioligand binding assays, demonstrating overexpression of angiotensin II receptors in the transgenic rats up to 46 times the amount seen in nontransgenic rats. Coupling of the human AT1 receptor to rat G proteins and signal transduction cascade was verified by sensitivity to GTP-γ-S and increased sensitivity of intracellular Ca2+ [Ca2+]i to angiotensin II in fluo-3 loaded transgenic cardiomyocytes. Transgenic rats exhibited normal cardiac growth and function under baseline conditions. Pronounced hypertrophic growth and contractile responses to angiotensin II, however, were noted in transgenic rats challenged by volume and pressure overload. In summary, we generated a new transgenic rat model that exhibits an upregulated myocardial AT1 receptor density and demonstrates augmented cardiac hypertrophy and contractile response to angiotensin II after volume and pressure overload, but not under baseline conditions.
European Journal of Heart Failure | 2012
Marcelle D. Smit; Marjolein L Moes; Alexander H. Maass; Ismael D. Achekar; Peter Paul van Geel; Hans L. Hillege; Dirk J. van Veldhuisen; Isabelle C. Van Gelder
Atrial fibrillation (AF) and heart failure often co‐exist. It is unknown whether the sequence in which AF and heart failure develop is of significance regarding prognosis. We assessed the prognosis of AF patients hospitalized for heart failure based on the timing of AF and heart failure development.
Lancet Infectious Diseases | 2017
Anna Gomes; Andor W. J. M. Glaudemans; Daan Touw; Joost P. van Melle; Tineke P. Willems; Alexander H. Maass; Ehsan Natour; Niek H. J. Prakken; Ronald Borra; Peter Paul van Geel; Riemer H. J. A. Slart; Sander van Assen; Bhanu Sinha
Sensitivity and specificity of the modified Duke criteria for native valve endocarditis are both suboptimal, at approximately 80%. Diagnostic accuracy for intracardiac prosthetic material-related infection is even lower. Non-invasive imaging modalities could potentially improve diagnosis of infective endocarditis; however, their diagnostic value is unclear. We did a systematic literature review to critically appraise the evidence for the diagnostic performance of these imaging modalities, according to PRISMA and GRADE criteria. We searched PubMed, Embase, and Cochrane databases. 31 studies were included that presented original data on the performance of electrocardiogram (ECG)-gated multidetector CT angiography (MDCTA), ECG-gated MRI, 18F-fluorodeoxyglucose (18F-FDG) PET/CT, and leucocyte scintigraphy in diagnosis of native valve endocarditis, intracardiac prosthetic material-related infection, and extracardiac foci in adults. We consistently found positive albeit weak evidence for the diagnostic benefit of 18F-FDG PET/CT and MDCTA. We conclude that additional imaging techniques should be considered if infective endocarditis is suspected. We propose an evidence-based diagnostic work-up for infective endocarditis including these non-invasive techniques.
European Journal of Heart Failure | 2014
Marie Louise Luttik; Tiny Jaarsma; Peter Paul van Geel; Maaike Brons; Hans L. Hillege; Arno W. Hoes; Richard M. de Jong; Gerard C.M. Linssen; Dirk J. Lok; Marjolein Berge; Dirk J. van Veldhuisen
It has been suggested that home‐based heart failure (HF) management in primary care may be an alternative to clinic‐based management in HF patients. However, little is known about adherence to HF guidelines and adherence to the medication regimen in these home‐based programmes. The aim of the current study was to determine whether long‐term follow‐up and treatment in primary care is equally effective as follow‐up at a specialized HF clinic in terms of guideline adherence and patient adherence, in HF patients initially managed and up‐titrated to optimal treatment at a specialized HF clinic.
Journal of the Renin-Angiotensin-Aldosterone System | 2004
Adriaan A. Voors; Peter Paul van Geel; M Oosterga; Hendrik Buikema; Dirk J. van Veldhuisen; Wiek H. van Gilst
Introduction The angiotensin-converting enzyme (ACE) DD-genotype is associated with increased plasma and myocardial ACE-activity. The influence of the ACE insertion/deletion (I/D) polymorphism on the effects of ACE-inhibition on vascular responses has not been previously described. Materials and methods In the randomised, double-blind QUinapril On Vascular ACE and Determinants of Ischemia Study (QUO VADIS), 149 patients undergoing coronary bypass surgery were randomised to receive either the ACE inhibitor, quinapril, or placebo. In 82 patients, we obtained ACE-genotype, and measured vascular responses to angiotensin II (Ang II) in left internal mammary arteries. Results In the placebo group, the mean maximal vasoconstriction to Ang II was significantly lower in patients with the DD-genotype than in those with the ID/II genotype (36.2±5.11% [n=13] vs. 55.6±4.57% [n=25]; p=0.01). In the quinapril group, the mean maximal vasoconstriction to Ang II was similar [n=8] vs. 57.7±4.07% [n=35]; p=0.85). between DD- and ID/II-genotype (59.6±9.19% Conclusions DD-genotype patients showed decreased vascular responses to Ang II but treatment with quinapril completely restored the decreased vascular response in DD-genotype patients to the same level as II/ID-genotype patients, while no effect of quinapril was demonstrated in the II/ID-genotype patients.
Journal of Cardiovascular Pharmacology | 2002
Rudolf A. de Boer; Peter Paul van Geel; Yigal M. Pinto; Albert J. H. Suurmeijer; Harry J.G.M. Crijns; Wiek H. van Gilst; Dirk J. van Veldhuisen
Angiotensin II induces ischemia/reperfusion (I/R)-induced arrhythmias and blockade of the angiotensin II type 1 receptor (AT1R) may therefore be beneficial in preventing arrhythmias and decreasing mortality after myocardial infarction (MI). Because the AT1R is upregulated after myocardial ischemia, it was hypothesized that the level of AT1R expression would mediate the response to AT1R blockade. Transgenic (TGR) rats that overexpress the human AT1R and Sprague–Dawley rats were used as controls. Total duration of arrhythmia (seconds) after I/R injury was similar in TGR and SD rats (433 ± 109 vs. 376 ± 117, p = n.s.). AT1R blockade with losartan decreased total duration of arrhythmia in the TGR rats (433 ± 110 s–164 ± 48 s; p < 0.05), whereas it caused a nonsignificant increase in the SD rats (376 ± 117 s–497 ± 97). In vivo, survival in the first 24 hours after MI was impaired in TGR rats (39%; SD, 63%). Losartan improved survival significantly in TGR rats (from 39% to 80%, p < 0.05). A smaller, nonsignificant effect was observed in SD rats (63% to 81%). AT1R blockade is beneficial only when the AT1R was overexpressed, both in reducing the reperfusion-induced arrhythmias and mortality early after MI.
Journal of the Renin-Angiotensin-Aldosterone System | 2005
Adriaan A. Voors; Peter Paul van Geel; Hendrik Buikema; Margreeth Oosterga; Dirk J. van Veldhuisen; Wiek H. van Gilst
Introduction. Animal studies demonstrated an interaction between angiotensin II (Ang II) responsiveness and endothelium-dependent relaxation (EDR). However, this relation has not been well described in humans. Therefore, we investigated the relation between Ang II responsiveness and EDR in isolated human arteries. Materials and Methods. Segments of the internal mammary artery (IMA) were harvested from 89 patients undergoing coronary bypass surgery. Rings of these segments were exposed in organ bath experiments to metacholine (ME; 10 nmol/L -0.1 mmol/L) after precontraction with phenylephrine (PE; 10 µmol/L), and secondly to increasing concentrations of Ang II (0.1 nmol/L —1 µmol/L). Results. Patients with the highest contraction to Ang II showed the lowest ME relaxation (r=0.312; p=0.003). Angiotensin-converting enzyme (ACE)-inhibition significantly increased Ang II sensitivity (p=0.03). This increase was accompanied by a tendency toward decreased EDR (p=0.07). The inverse relation between Ang responsiveness and endotheliumdependent relaxation could not be explained by an increased tissue or serum ACE-inhibition in patients with a higher endothelium-dependent relaxation. Conclusions. High Ang II responsiveness inversely correlates to EDR in IMAs of patients with established coronary artery disease. Short-term treatment with an ACE-inhibitor increased the response to Ang II, but had an adverse effect on EDR.
Journal of Nuclear Cardiology | 2018
Anna Gomes; Peter Paul van Geel; Michiel Santing; Niek H. J. Prakken; Mathilde L. Ruis; Sander van Assen; Riemer H. J. A. Slart; Bhanu Sinha; Andor W. J. M. Glaudemans
Background Multimodality imaging is recommended to diagnose infective endocarditis. Value of additional imaging to echocardiography in patients selected by a previously proposed flowchart has not been evaluated. Methods An observational single-center study was performed. Adult patients suspected of endocarditis/device infection were prospectively and consecutively enrolled from March 2016 to August 2017. Adherence to a diagnostic imaging-in-endocarditis-flowchart was evaluated in 176 patients. Imaging techniques were compared head-to-head in 46 patients receiving echocardiography (transthoracic plus transesophageal), multi-detector computed tomography angiography (MDCTA), and 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET/CT). Results 69% of patients (121/176) adhered to the flowchart. Sensitivity of echocardiography, MDCTA, FDG-PET/CT in patients without prosthesis was 71%, 57%, 29% (86% when combined), while specificity was 100%, 75%, 100%, respectively. Sensitivity in patients with prosthesis was 75%, 75%, 83%, respectively (100% when combined), while specificity was 86% for all three modalities. Echocardiography performed best in the assessment of vegetations, morphological valve abnormalities/dehiscence, septum defects, and fistula formation. MDCTA performed best in the assessment of abscesses and ventricular assist device infection. FDG-PET/CT performed best in the assessment of cardiac device infection, extracardiac infectious foci, and alternative diagnoses. Conclusions This study demonstrates that the evaluated imaging-in-endocarditis-flowchart is applicable in daily clinical practice. Echocardiography, MDCTA, and FDG-PET/CT provide relevant complementary diagnostic information, particularly in patients with intracardiac prosthetic material.
Circulation | 2018
Laurens E. Swart; Anna Gomes; Asbjørn M. Scholtens; Bhanu Sinha; Wilco Tanis; Marnix G. E. H. Lam; Maureen J. van der Vlugt; Sebastian A.F. Streukens; Erik H.J.G. Aarntzen; Jan Bucerius; Sander van Assen; Chantal P. Bleeker-Rovers; Peter Paul van Geel; Gabriel P. Krestin; Joost P. van Melle; Jolien W. Roos-Hesselink; Riemer H. J. A. Slart; Andor W. J. M. Glaudemans; Ricardo P.J. Budde
Background: 18F-Fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) was recently introduced as a new tool for the diagnosis of prosthetic heart valve endocarditis (PVE). Previous studies reporting a modest diagnostic accuracy may have been hampered by unstandardized image acquisition and assessment, and several confounders, as well. The aim of this study was to improve the diagnostic performance of FDG PET/CT in patients in whom PVE was suspected by identifying and excluding possible confounders, using both visual and standardized quantitative assessments. Methods: In this multicenter study, 160 patients with a prosthetic heart valve (median age, 62 years [43–73]; 68% male; 82 mechanical valves; 62 biological; 9 transcatheter aortic valve replacements; 7 other) who underwent FDG PET/CT for suspicion of PVE, and 77 patients with a PV (median age, 73 years [65–77]; 71% male; 26 mechanical valves; 45 biological; 6 transcatheter aortic valve replacements) who underwent FDG PET/CT for other indications (negative control group), were retrospectively included. Their scans were reassessed by 2 independent observers blinded to all clinical data, both visually and quantitatively on available European Association of Nuclear Medicine Research Ltd–standardized reconstructions. Confounders were identified by use of a logistic regression model and subsequently excluded. Results: Visual assessment of FDG PET/CT had a sensitivity/specificity/positive predictive value/negative predictive value for PVE of 74%/91%/89%/78%, respectively. Low inflammatory activity (C-reactive protein <40 mg/L) at the time of imaging and use of surgical adhesives during prosthetic heart valve implantation were significant confounders, whereas recent valve implantation was not. After the exclusion of patients with significant confounders, diagnostic performance values of the visual assessment increased to 91%/95%/95%/91%. As a semiquantitative measure of FDG uptake, a European Association of Nuclear Medicine Research Ltd–standardized uptake value ratio of ≥2.0 was a 100% sensitive and 91% specific predictor of PVE. Conclusions: Both visual and quantitative assessments of FDG PET/CT have a high diagnostic accuracy in patients in whom PVE is suspected. FDG PET/CT should be implemented early in the diagnostic workup to prevent the negative confounding effects of low inflammatory activity (eg, attributable to prolonged antibiotic therapy). Recent valve implantation was not a significant predictor of false-positive interpretations, but surgical adhesives used during implantation were.Laurens E. Swart, MD; Anna Gomes, MD, PhD; Asbjørn M. Scholtens, MD; Bhanu Sinha, MD, PhD; Wilco Tanis, MD, PhD; Marnix G.E.H. Lam, MD, PhD; Maureen J. van der Vlugt, MD, PhD; Sebastian A.F. Streukens, MD; Erik H.J.G. Aarntzen, PhD; Jan Bucerius, MD, PhD; Sander van Assen, MD, PhD; Chantal P. Bleeker-Rovers, MD, PhD; Peter Paul van Geel, MD, PhD; Gabriel P. Krestin, MD, PhD; Joost P. van Melle, MD, PhD, Jolien W. Roos-Hesselink, MD, PhD; Riemer H.J.A. Slart, MD, PhD; Andor W.J.M. Glaudemans, MD, PhD; Ricardo P.J. Budde MD PhD